T1	Participants 89 104	Hodgkin disease
T3	Participants 393 523	Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation
T4	Participants 358 382	tertiary referral center
T2	Participants 167 286	granulocyte macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed or refractory Hodgkin disease.
